Provenge sipuleucel-T: Phase II data

An open-label, U.S. Phase II trial in 29 patients with asymptomatic or minimally symptomatic metastatic CRPC showed that there was no significant difference on the primary endpoint of median cumulative CD54 up-regulation, a measure of antigen presenting cell activation, between patients who received Provenge concurrently with Zytiga abiraterone acetate plus prednisone and patients who received Provenge 10 weeks prior to initiation of Zytiga plus prednisone (31.6 vs. 36.6 cells). Additionally, there was no significant difference between the concurrent and sequential treatment groups on the secondary endpoint of CD54-positive cell count. The overall incidence of adverse events was similar between the arms. Dendreon said that the data suggest that Zytiga does not interfere with the potency of Provenge. Data were presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium in Orlando. ...